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Inpatientsonmaintenancehemodialysisseveralfactorsreducethebodystoredcarnitinewhichcouldleadtodyslipidemia,anemia,
and general health in these patients. We evaluated the eﬀect of oral L-carnitine supplementation on lipid proﬁles, anemia, and
quality of life (QOL) in hemodialysis patients. In a randomized, double-blinded, placebo-controlled trial, end-stage renal disease
(ESRD) patients on hemodialysis received either L-carnitine 1g/d (n = 24) or placebo (27 patients) for 16 weeks. At the end
of the study, there was a signiﬁcant decrease in triglyceride (−31.1 ± 38.7mg/dL, P = 0.001) and a signiﬁcant increase in HDL
(3.7 ± 2.8mg/dL, P<0.001) levels in the carnitine group. Decrease in total cholesterol (−6.6 ± 16.0mg/dL, P = 0.075) and
increase in hemoglobin (0.7 ± 1.7g/dL, P = 0.081) concentrations in the carnitine group were not signiﬁcant. There was no
statistically signiﬁcant changes in LDL in any group (P>0.05). Erythropoietin dose was signiﬁcantly decreased in both the
carnitine (−4750 ± 5772mg, P = 0.001) and the placebo group (−2000 ± 4296mg, P<0.0 5 ) .N oi m p r o v e m e n tw a so b s e r v e d




The prevalence and incidence of chronic kidney diseases
(CKDs) is increasing all over the world and in Iran as well
[1]. In spite of medical advancements and increased survival
rate of the patients, atherosclerosis and the subsequent
cardiovascular diseases are still the most important causes
of mortality in CKD patients and end-stage renal disease
(ESRD) [2, 3].
Dyslipidemia is commonly observed in ESRD patients,
which is one of the major underlying causes of development
and progression of atherosclerosis in this group of patients.
Almost 40% of patients on continuous hemodialysis have
some types of dyslipidemia, and most of them are aﬀected
by hyperlipidemia type IV and decreased high-density
lipoprotein (HDL) plasma level [3]. Development and
progression of dyslipidemia in these patients is inﬂuenced
by various factors such as carnitine deﬁciency which could
lead to abnormalities in lipid metabolism [4, 5]. Carnitine
or trimethyl-aminobutyric acid is a natural and essential
vitamin-like substance for human body. It is involved in
many metabolic processes including regulation of ketogen-
esis, conformation and control of mitochondrial energy, and
transportation of long-chain free fatty acids from cytoplasm2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
into mitochondria for beta-oxidation. Therefore, presence
of suﬃcient amounts of carnitine in cells is essential for
normal oxidation of fatty acids. The substance is of great
importance in tissues such as cardiac or skeletal muscles,
which rely on fatty acid metabolism for energy production
[6]. Moreover, several metabolic disorders such as oxidative
stress and transformation of phospholipids that are caused
following carnitine deﬁciency can aﬀect the development
and progression of anemia as another commonly observed
complication in patients with ESRD [7].
Since the kidney is one of the main sites of carnitine
synthesis, endogenous carnitine production is signiﬁcantly
reducedafterthekidneyparenchymaldamage[5].Moreover,
since carnitine is synthesized from lysine and methionine
in human body, the body requires exogenous carnitine to
achieve a daily balance of carnitine. Meat and milk products
arerichsourcesofexogenouscarnitineanditsprecursors[6].
Nevertheless, poor nutritional state is common in patients
with hemodialysis [8]. Thus, patients under hemodialysis
receive limited amounts of food containing carnitine and
its precursors. Also, the cofactors and carnitine precursors
suchasvitaminB6,niacin,vitaminC,lysine,andmethionine
may be removed during hemodialysis process [5]. The small
molecule of carnitine is very polar and water-soluble and
can freely pass the dialysis membrane, such that in each
hemodialysis session, the serum level of carnitine is decrease
by 75% [5].
Several studies have been conducted on the eﬀects of car-
nitine supplement administration on dyslipidemia, skeletal
muscle function, cardiac function, and anemia in patients
under continuous hemodialysis. The eﬀect of carnitine sup-
plementation on dyslipidemia has been remained unknown
[9]. In addition, there is also a lack of data on the eﬀects of
carnitine supplementation on quality of life (QOL) in ESRD
patients.
Considering the possible role of carnitine deﬁciency in
development of dyslipidemia in ESRD and contrary ﬁndings
of previous studies in this respect, this study was carried out
to determine the eﬀect of oral L-carnitine supplement on
lipid proﬁle, anemia, and life quality of dyslipidemic ESRD
patients under continuous hemodialysis.
2.Methods and Materials
2.1. Patients and Setting. This randomized, placebo-con-
trolled, double-blinded, clinical trial was carried out on dys-




session almost 4 hours, and serum TG or total cholesterol
concentration >200mg/dL or serum HDL concentration
<40mg/dL at the beginning of the study. The patients
were not included into the study if they were on carnitine
supplement or any drug that interacts with carnitine, that
is, anticoagulant medication or those lowering the seizure
threshold (e.g., tricydic antidepressants) in the last month.
Patientsonotherdrugsinﬂuencinglipidmetabolism,suchas
β-blockers, glucocorticoids, or lipid-lowering agents during
the previous eight weeks were not enrolled. Furthermore,
patients with liver dysfunction, hypothyroidism, chronic
infectiousdiseasessuchashepatitis,activesourceofinfection
or inﬂammatory diseases, or history of seizure and known
cases of any brain mass according to medical history were
not included. Sampling was performed with convenient
nonrandomized method from among the patients referred
to the dialysis ward of the hospitals. Considering the
study power of 80%, type one error of 5%, and at least
5mg/dL increase in HDL concentration, according to the
previous studies [7], and also with respect to 10% of
dropouts, the sample size for each group was determined
to be 25. The study was approved by the Ethical Com-
mittee of Isfahan University of Medical Sciences, regis-
tered in http://www.clinicaltrial.org/ (NCT01278693),a n d
all patients signed a fully informed written consent before
including to the study.
2.2. Intervention. Eligible patients were assigned to either
carnitine or placebo groups based on the random number
table, generated by random allocation software [10]. The
patients in the carnitine group received 1g of carnitine oral
supplement each day (two 250mg tablets twice a day, for
16 weeks), and the patients in the placebo group received
the placebo mad by the same company in the same manner
and duration. L-carnitine and placebo were coded and
the physician, researchers, and patients were blinded to
the code of carnitine and the placebo. The patients were
followed up for drug side eﬀects and the compliance for
drug consumption every two weeks in the treatment centers.
In case of occurrence of severe complications associated
withcarnitineincludingseveregastrointestinalupset,muscle
weakness, and seizure or discontinuation of the drug for
morethanoneweek,thesubjectwasexcludedfromthestudy.
2.3. Clinical and Laboratory Evaluations. Demographic char-
acteristics, including age, sex, body mass index (BMI), the
underlying cause of ESRD, and duration of dialysis were
recorded at the beginning of the study. Moreover, total
cholesterol, HDL, low-density lipoprotein (LDL), TG, and
hemoglobin (Hb) serum concentrations, as well as the
received erythropoietin dose was recorded at the onset of
the study and 8 and 16 weeks after the beginning of the
intervention. To assess the QOL of patients, we used the
Short-Form Health Survey (SF-36) [11] questionnaire at the
beginning, and 8 and 16 weeks after the beginning of the
study.
2.4. Statistical Analysis. To compare baseline and demo-
graphical characteristics of the participants between the
two groups, we used chi-square and independent sample t-
test. For evaluation of variable changes in the two groups,
we used repeated measures and paired t-test. Multivariate
analysis was done for controlling covariate factors. The data
was analyzed using SPSS software, version 16.0 (SPSS Inc.,
Chicago, IL, USA). The P value less than 0.05 considered
statistically signiﬁcant.J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
Table 1: Demographic characteristics in two groups.
Carnitine Placebo P
n = 24 n = 27
Age (year) 53.9 ±17.25 1 .8 ±13.5 0.627
Gender
Male 12 (50%) 14 (51.8%) 0.559
Female 12 (50%) 13 (48.1%)
BMI 23.0 ±4.32 5 .4 ±3.6 0.383
Hemodialysis (month) 32.5 ±25.92 8 .1 ±13.3 0.441
Etiology of ESRD
Diabetes 12 (50%) 15 (55.5%)
0.645 Hypertension 6 (25%) 6 (22.2%)
Polycystic kidney 1 (4.1%) 3 (11.1%)
Miscellaneous 5 (20.8%) 3 (11.1%)
Table 2: The changes in lipid proﬁle, hemoglobin, and consumed erythropoietin in two groups.
Carnitine Placebo
n = 24 n = 27
Baseline 8th week 16th week P Baseline 8th week 16th week P
Triglyceride, mg/dL 165.5 ±71.3 147.2 ±60.2 138.3 ±54.3 0.001 142.2 ±58.0 161.3 ±52.4 151.8 ±48.2 0.029
Cholesterol, mg/dL 147.1 ±40.8 154.0 ±30.2 154.5 ±30.1 0.075 154.8 ±25.1 155.3 ±29.3 151.2 ±24.9 0.517
HD, mg/dL 30.2 ±6.63 1 .0 ±5.83 4 .0 ±6.6 <0.001 29.5 ±7.23 0 .1 ±6.12 8 .6 ±8.4 0.185
LDL, mg/dL 84.0 ±24.78 3 .5 ±20.28 1 .0 ±20.7 0.237 97.6 ±26.19 2 .1 ±30.09 0 .6 ±28.9 0.227
Hemoglobin, mg/dL 10.5 ±2.51 0 .9 ±2.41 1 .3 ±2.1 0.081 9.5 ±2.21 0 .1 ±1.99 .9 ±2.5 0.145
Dose of erythropoietin, U/wk 7250 ±5202 4750 ±3813 2500 ±4180 <0.001 8000 ±3186 6888 ±4308 6000 ±5083 0.033
3. Results
Twenty-seven patients were entered into each group. In the
carnitinegroup,threepatientswereexcluded;oneunderwent
kidney transplantation, one died because of myocardial
infarction, and one was not willing to continue the study.
Thus, we analyzed the information of 24 patients in the
carnitine group and 27 patients in the placebo group. As it is
reported in Table 1, two groups were not signiﬁcantly diﬀer-
entwithrespectto demographicalorbaseline characteristics,
except for BMI which was higher in the carnitine group
(P = 0.383). We omitted two extra value cases of obesity in
carnitine group, and analysis was repeated again but there
were not signiﬁcant changes in ﬁnal result comparing to the
previous analysis.
Of total, 5 patient in carnitine group and 6 patients in
placebo group had high triglyceride (TG), high cholesterol,
and low HDL levels. There was no diﬀerence between
baseline TG and Hb levels in 2 groups (TG: P = 0.204; Hb:
P = 1.84).Thechangesinlipidproﬁle,Hb,andreceiveddose
of erythropoietin are shown in Table 2. Also, comparison
of the amount of changes in these variables between the
two groups is presented in Table 3. The concentration of TG
was signiﬁcantly decreased in the carnitine group (−31.1 ±
38.7mg/dL,P = 0.001), while it was increased in the placebo
group (9.6±32.2mg/dL,P = 0.029). Decrease in cholesterol
level in the carnitine group was not statistically signiﬁcant
(−6.6 ± 16.0mg/dL, P = 0.075 for repeated measure test
and = 0.055 for paired t-test), and there was no signiﬁcant
change in the placebo group as well (−3.6 ± 24.9mg/dL,
P = 0.517). The HDL concentration in the carnitine group
increased signiﬁcantly by 3.7 ± 2.8mg/dL(P<0.001), but
it did not change signiﬁcantly in the placebo group (P =
0.185). The LDL concentration, however, did not change in
any group (P = 0.237 in the carnitine group; P = 227 in
the placebo group). According to repeated measure analysis,
the changes in Hb level was not statistically signiﬁcant in the
carnitine group (P = 0.081), but with paired t-test, there was
a signiﬁcant increase in Hb level after the study (P = 0.037).
NosigniﬁcantchangewasobservedinHblevelintheplacebo
group (P = 0.145). The required dose of erythropoietin
signiﬁcantly decreased in both groups, by a greater amount
of decrease in the carnitine group (−4750 ± 5772; P = 0.001
versus −2000 ±4296U/Wk; P = 0.033).
The changes of overall scores of QOL and its physical and
mental subscales in the two groups are presented in Table 4.
Also, comparison of the changes between the two groups
is demonstrated in Table 5. The overall QOL score changed
signiﬁcantly in both groups (P = 0.148 in carnitine group;
P = 0.087 in placebo group). Score of the physical health
domain decreased in the carnitine group (P = 0.033), and
score of the mental health domain decreased in the placebo
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Table 3: Comparing lipid proﬁle, hemoglobin, and consumed erythropoietin between two groups.
Carnitine Placebo P
n = 24 n = 27
Triglyceride, mg/dL −31.1 ±38.79 .6 ±32.2 <0.001
Cholesterol, mg/dL −6.6 ±16.0 −3.6 ±24.9 .311
HDL, mg/dL 3.7 ±2.8 −0.8 ±3.7 <0.001
LDL, mg/dL −3.0 ±10.4 −6.9 ±24.7 0.239
Hemoglobin, mg/dL 0.7 ±1.70 .3 ±1.4 0.190
Dose of erythropoietin, U/wk 4750 ±5772 −2000 ±4296 0.029
Table 4: The changes of overall scores of quality of life and its physical and mental subscales in two groups.
Carnitine Placebo
n = 24 n = 27
Baseline 8th week 16th week P Baseline 8th week 16th week P
Total SF-36 55.5 ±24.85 1 .7 ±18.55 5 .7 ±19.4 0.148 38.8 ±14.03 7 .5 ±14.03 6 .2 ±16.0 0.087
Physical subscales 56.6 ±23.95 1 .2 ±18.75 2 .5 ±18.0 0.033 36.6 ±12.13 6 .6 ±12.43 4 .5 ±13.3 0.180
Mental subscales 51.6 ±24.35 3 .8 ±19.75 8 .2 ±21.2 0.128 42.5 ±15.13 9 .0 ±14.43 7 .6 ±17.3 <0.001
Table 5: Comparison of the changes between scores of quality of
life and its physical and mental subscales between two groups.
Carnitine Placebo P
n = 24 n = 27
Total SF-36 0.2 ±12.1 −2.6 ±7.7 0.152
Physical subscales −4.1 ±11.78 .5 ±2.1 0.241
Mental subscales 2.1 ±10.1 −4.6 ±6.1 0.002
Considering diﬀerences between the two groups in
BMI and baseline lipid proﬁles, we conducted multivariate
analysis to determine the eﬀect of carnitine on each of
the lipid proﬁle components controlling by age, sex, BMI,
duration of hemodialysis, and baseline level of the related
variable. According to the results, baseline level of TG (t =
6.2, P<0.001), receiving carnitine (t = 2.2, P = 0.040), and
female gender (t = 4.8, P<0.001) signiﬁcantly predicted
decrease in TG level after study. For decrease in cholesterol
level after study, baseline cholesterol level (t = 2.4, P =
0.025) and duration of hemodialysis (t = 3.7, P = 0.002)
were predictors, but receiving carnitine did not signiﬁcantly
predict changes in cholesterol level (t = 1.7, P = 0.095).
Baseline HDL level (t =− 3.4, P = 0.003), BMI (t =− 4.1,
P = 0.001),malegender(t =− 4.1,P = 0.001),andreceiving
carnitine (t = 3.3, P = 0.004) were predictors of increase
in the HDL level after study. Only duration of hemodialysis
was a predictor for lower LDL level after study (t = 2.8,
P = 0.012) and receiving carnitine was not associated to
changes in LDL level (t = 0.298, P = 0.769).
4. Discussion
Our results indicated that L-carnitine decreased the concen-
trations of TG and signiﬁcantly increased HDL concentra-
tion. The decrease in cholesterol level was not statistically
signiﬁcant which might be due to the small sample size. L-
carnitine did not have a signiﬁcant eﬀect on LDL concentra-
tion.
Itiswellknownthatcarnitineinvolvesinmanymetabolic
processes. There is a negative correlation between serum
free carnitine and total TG levels in iron-deﬁcient patients
[12]. It has been shown that carnitine could signiﬁcantly
reduce TG in plasma and tissues of sedentary rats and intake
of hydrogenated fat diet in rats signiﬁcantly increased the
plasma and tissue lipid proﬁle and monounsaturated fatty
acids-rich diet or carnitine supplementation and/or exercise
may ameliorate the deleterious eﬀects of hydrogenated fat
[13].
Carnitine supplementation further augmented the
oxidative capacity of both liver and muscle signiﬁcantly by
enhancing the activity of carnitine palmitoyl transferase
and the respiratory chain enzymes. These eﬀects can be
attributed to the enhanced unsaturated fatty acids in
phospholipids of mitochondria and may be due to increased
ﬂuidity of the membrane in these rats [14].
Previous studies reported diﬀerent eﬀects of carnitine
supplementation on lipid proﬁle. Similarly to our results,
the results of a meta-analysis showed that carnitine supple-
mentation in patients on hemodialysis leads to a decrease
in TG and cholesterol levels and also an increase in HDL
level, without any signiﬁcant change on the LDL level
[15]. Nevertheless, another systematic review on carnitine
supplementation did not report signiﬁcant eﬀect of carnitine
onTG,cholesterol,oritsderivatives[9].Theheterogeneityof
the results of clinical trials can be explained by the diﬀerence
of the studies with respect to baseline lipid proﬁle status,
the administered dose of carnitine supplement, the route of
administration (oral or venous), and the speciﬁc character-
istics of population under evaluation [9]. In some studies,
the carnitine supplement was eﬀective for modiﬁcation of
lipid proﬁle of the patients with baseline TG level more thanJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
200mg/dL or HDL level less than 35mg/dL [7]. Accordingly,
we carried out our intervention on such patients, and our
results indicated positive eﬀect of carnitine on lipid proﬁle.
However, multivariate analysis in our study showed that
carnitine decreased the TG level and increased the HDL
level regardless of the baseline levels of each variable. In a
recent randomized placebo-controlled trial, the eﬃcacy of
carnitine therapy was studied. After 3 months, serum level
of lipoprotein(a) reduced signiﬁcantly but serum level of TG
and other lipoproteins did not signiﬁcantly alter. However,
they used carnitine as add-on therapy with atorvastatin or
lovastatin to assess the eﬃcacy of supplement therapy [16].
The eﬀect of carnitine on anemia of patients under
continuous hemodialysis was evaluated in previous studies,
and the results indicated that carnitine supplementation
enhances the response to administered dose of erythropoi-
etin in these patients, which ends in increased hematocrit,
r e d u c e dd o s eo fr e q u i r e de r y t h r o p o i e t i n ,a n dd e c r e a s e d
index of erythropoietin resistance [7]. In our study, L-
carnitine supplementation increased hemoglobin concentra-
tion. Although the required dose of erythropoietin signiﬁ-
cantly decreased in both groups, the amount of decrease was
greater in the carnitine group.
The eﬀect of L-carnitine on QOL of ESRD patients is
an important topic which received less attention in previous
studies. In a randomized, placebo-controlled, cross-over
design trial, Semeniuk and colleagues used intravenous
L-carnitine (20mg/kg) comparing to placebo after each
dialysis session for 12 weeks. But there was no signiﬁcant
eﬀe c to nQ O L .I ti so fn o t et h a tl e n g t ho fs t u d yw a sl e s s
than our trial. Also the route, interval, and dose of prescrip-
tion were diﬀerent from our study. In addition they used
speciﬁc inclusion criteria containing intradialytic hypoten-
sion, muscle cramping, lack of energy, muscle weakness
or myopathy, cardiomyopathy, or lack of responsiveness to
erythropoietin. The considered criteria are important direct
consequences and comorbidities in patients with ESRD
on chronic hemodialysis that can inﬂuence on QOL [17].
In another study, the SF-36 questionnaire was used, and
administration of L-carnitine for eight weeks led to 18.2
points increase in the total QOL score [18]. In a controlled
trial, after six weeks of administration, L-carnitine sup-
plementation led to positive eﬀects on QOL, but after 24
months of supplementation, the eﬀect was not detectable
[19]. We observed that L-carnitine supplementation did not
have a considerable eﬀect on the overall score of QOL of the
patients. Considering the reported eﬀects of L-carnitine on
muscular weakness, cardiac function, and anemia, positive
eﬀects on the patients’ physical health were expected, but
conversely we observed about four-point decrease in the
score of this domain in the carnitine group. The score of
mental health domain of QOL signiﬁcantly decreased in the
placebo group, but the change in the carnitine group was not
signiﬁcant.
It should be considered that L-carnitine has some anti-
inﬂammatory eﬀect that can inﬂuence on our results. In a
study by Savica et al., maintenance hemodialysis patients
were assigned to receive intravenous injections of L-carnitine
20mg/kg comparing to placebo thrice weekly at the end of
each hemodialysis treatment for 6 months. The carnitine-
treated group showed a statistically signiﬁcant decrease in
serum C-reactive protein and increase in serum albumin
and transferrin, blood Hb, and body mass index. They
reported that in hemodialysis patients, L-carnitine ther-
apy may suppress inﬂammation, particularly among those
patientswithC-reactiveprotein ≥3mg/dL,andmayimprove
protein-energy nutritional status [20]. Although we did
not monitored inﬂammatory biomarkers in this group of
patients, we excluded patients with evidence of active infec-
tion diseases or history of inﬂammatory diseases. However,
weconnotdiscussthepossibleroleofinﬂammationandanti-
inﬂammatory eﬀects of L-carnitine on lipid proﬁle, anemia
and QOL in hemodialysis patients.
Our study has some limitations. The randomization was
not eﬀective to match patients in both groups in the case
of BMI and lipid proﬁle. Furthermore, because of the small
sample size, a precise multivariate analysis to evaluate the
predictive factors of response to treatment was not possible.
Some possible contributory factors such as folate and iron
were not measured.
5. Conclusion
In dyslipidemic ESRD patients under continuous hemodial-
ysis, oral L-carnitine supplementation can decrease TG and
increaseHDLlevels,withoutsigniﬁcanteﬀectsoncholesterol
or LDL levels. In spite of the observed positive eﬀects of oral
L-carnitine on lipid proﬁle and anemia, it did not have a
positive eﬀect on the patients’ QOL in our study. Comple-
mentary studies with larger sample size, longer follow up,
and evaluation of other important treatment outcomes such
as cardiopulmonary function and the kidney disease speciﬁc
QOL are necessary.
Acknowledgments
This study was supported by the Isfahan University of
Medical Sciences, Isfahan, Iran. The authors appreciate the
kind cooperation of patients and staﬀ of hemodialysis wards
of Noor and Al-Zahra hospitals, Isfahan, Iran. They thank
Mojtaba Akbari for statistical analysis.
References
[1] F. Hosseinpanah, F. Kasraei, A. A. Nassiri, and F. Azizi,
“High prevalence of chronic kidney disease in Iran: a large
population-based study,” BMC Public Health, vol. 9, no. 1,
article 44, 2009.
[2] T. Shoji and Y. Nishizawa, “Chronic kidney disease as a
metabolic syndrome with malnutrition—need for strict con-
trol of risk factors,” Internal Medicine, vol. 44, no. 3, pp. 179–
187, 2005.
[3] V. Tsimihodimos, E. Dounousi, and K. C. Siamopoulos, “Dys-
lipidemia in chronic kidney disease: an approach to pathogen-
esis and treatment,” American Journal of Nephrology, vol. 28,
no. 6, pp. 958–973, 2008.
[4] N. D. Vaziri and H. Moradi, “Mechanisms of dyslipidemia of
chronic renal failure,” Hemodialysis International, vol. 10, no.
1, pp. 1–7, 2006.6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
[5] G. Bellinghieri, D. Santoro, M. Calvani, A. Mallamace, and
V. Savica, “Carnitine and hemodialysis,” American Journal of
Kidney Diseases, vol. 41, no. 3, supplement, pp. S112–S126,
2003.
[6] A.Arduini,M.Bonomini,V.Savica,A.Amato,andV.Zammit,
“Carnitine in metabolic disease: potential for pharmacological
intervention,” Pharmacology and Therapeutics, vol. 120, no. 2,
pp. 149–156, 2008.
[7] S. E. Reuter, R. J. Faull, and A. M. Evans, “L-carnitine supple-
mentation in the dialysis population: are Australian patients
missing out?” Nephrology, vol. 13, no. 1, pp. 3–16, 2008.
[8] M. Bossola, M. Muscaritoli, L. Tazza et al., “Malnutrition
in hemodialysis patients: what therapy?” American Journal of
Kidney Diseases, vol. 46, no. 3, pp. 371–386, 2005.
[9] J. M. Hurot, M. Cucherat, M. Haugh, and D. Fouque, “Eﬀects
of L-carnitine supplementation in maintenance hemodialysis
patients: a systematic review,” Journal of the American Society
of Nephrology, vol. 13, no. 3, pp. 708–714, 2002.
[10] M. Saghaei, “Random allocation software for parallel group
randomized trials,” BMC Medical Research Methodology, vol.
4, article 26, 2004.
[11] A. Montazeri, A. Goshtasebi, M. Vahdaninia, and B. Gandek,
“The Short Form Health Survey (SF-36): translation and val-
idation study of the Iranian version,” Quality of Life Research,
vol. 14, no. 3, pp. 875–882, 2005.
[12] F. Tanzer, S. Hizel, O. C ¸etinkaya, and E. Sekreter, “Serum
free carnitine and total triglycerid levels in children with
iron deﬁciency anemia,” International Journal for Vitamin and
Nutrition Research, vol. 71, no. 1, pp. 66–69, 2001.
[13] J. Karanth and K. Jeevaratnam, “Eﬀect of dietary lipid,
carnitine and exercise on lipid proﬁle in rat blood, liver and
muscle,” Indian Journal of Experimental Biology, vol. 47, no. 9,
pp. 748–753, 2009.
[14] J. Karanth and K. Jeevaratnam, “Eﬀect of carnitine supple-
mentation on mitochondrial enzymes in liver and skeletal
muscle of rat after dietary lipid manipulation and physical
activity,” Indian Journal of Experimental Biology, vol. 48, no.
5, pp. 503–510, 2010.
[15] Z. A. Massy, J. Z. Ma, T. A. Louis, and B. L. Kasiske, “Lipid-
lowering therapy in patients with renal disease,” Kidney Inter-
national, vol. 48, no. 1, pp. 188–198, 1995.
[16] M. Shojaei, M. Djalali, M. Khatami, F. Siassi, and M.
Eshraghian, “Eﬀects of carnitine and coenzyme Q10 on lipid
proﬁle and serum levels of lipoprotein(a) in maintenance
hemodialysis patients on statin therapy.,” Iranian journal of
kidney diseases, vol. 5, no. 2, pp. 114–118, 2011.
[ 1 7 ] J .S e m e n i u k ,K .F .S h a l a n s k y ,N .T a y l o r ,J .J a s t r z e b s k i ,a n dE .C .
Cameron, “Evaluation of the eﬀect of intravenous l-carnitine
on quality of life in chronic hemodialysis patients,” Clinical
Nephrology, vol. 54, no. 6, pp. 470–477, 2000.
[ 1 8 ]R .R a t h o d ,M .S .B a i g ,P .N .K h a n d e l w a l ,S .G .K u l k a r n i ,P .R .
Gade, and S. Siddiqui, “Results of a single blind, randomized,
placebo-controlled clinical trial to study the eﬀect of intra-
venous L-carnitine supplementation on health-related quality
oflifeinIndianpatientsonmaintenancehemodialysis,”Indian
Journal of Medical Sciences, vol. 60, no. 4, pp. 143–153, 2006.
[19] R. S. Sloan, B. Kastan, S. I. Rice et al., “Quality of life during
andbetweenhemodialysistreatments:roleofL-carnitinesup-
plementation,” American Journal of Kidney Diseases, vol. 32,
no. 2, pp. 265–272, 1998.
[20] V. Savica, D. Santoro, G. Mazzaglia et al., “L-carnitine infu-
sions may suppress serum C-reactive protein and improve nu-
tritional status in maintenance hemodialysis patients,” Journal
of Renal Nutrition, vol. 15, no. 2, pp. 225–230, 2005.